Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 1997

View Archived Issues

German launch for Femara

FDA advisory committee rejects Amphotec supplemental NDA

Vertex and BioChem Pharma test VX-710 for breast cancer and soft tissue sarcoma

Medarex presents MDX-220 preclinical data at AACR

Agouron anticancer research presented at AACR

Novavax completes phase Ia trial of generic human testosterone drug

Antidiabetic coumarin derivatives from Otsuka

Stable prostacyclins disclosed by Asahi Glass

Teijin and Microbial Chemistry Research Foundation reveal acetyl-CoA carboxylase inhibitor

Imitrex Nasal Spray introduced in Canada

U.K. approval for Edronax

Draxis Health to acquire Merck Frosst Canada radiopharmaceuticals division

Merck Genome Research Institute and Lexicon Genetics enter functional genomics agreement

Alliance temporarily suspends enrollment in its LiquiVent clinical trial

Cholesterol biosynthesis inhibitors described by Nippon Soda

Mercian discloses novel anthracycline antibiotics

Ribozyme and Schering AG to collaborate on target validation and therapeutic development

AntiCancer receives grant for development of mouse cancer model

Antitumor/antibacterial agent isolated by Microbial Chemistry Research Foundation

New opioid analgesic from Glaxo Wellcome

Dyax and Debiopharm collaborate to develop treatments for pulmonary disorders

MS&D designs potent and selective dopamine D4 antagonist

Preclinical results reveal mechanism of action and resistance profile of GEM-91

Biora introduces Emdogain in the U.S.

Caspase-1 involved in the regulation of multiple cytokines

Antimetastatic activity of Neovastat reported at AACR meeting

Inflazyme licences anticancer drugs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...